Alzheimer-associated APP+1 transgenic mice: Frameshift β-amyloid precursor protein is secreted in cerebrospinal fluid without inducing neuropathology

Abstract

Biomarkers present in the cerebrospinal fluid (CSF) of Alzheimer Disease patients could be instrumental in guiding diagnosis and monitoring of progression of the disease. We have previously reported on the secretion of a frameshifted form of amyloid-beta precursor protein, APP +1, into the CSF of Alzheimer patients and controls. APP +1 is secreted efficiently in controls, but during the progression of Alzheimer Disease, its secretion is reduced and APP +1 accumulates in tangle-bearing neurons. Here we describe the generation of a transgenic mouse line expressing APP +1 in the brain. These mice do not suffer from overt pathology or neurodegeneration, suggesting that APP +1 is not neurotoxic. To measure APP +1 levels in the CSF, we serially sampled CSF from the cisterna magna in the same mouse over a period of months. Indeed, APP +1 is secreted into the CSF of the transgenic mice, and APP +1 levels are stable over 1 year. This mouse model may guide the study of secretion deficits as found in Alzheimer Disease.